A hallmark of the VEITHsymposium has always been its focus on the results of recent and ongoing clinical trials, and this year is no exception. These trials will be presented by experts in their various fields who will discuss how the results will affect your daily practice.
A plethora of such clinical trials take center stage throughout the week and Tuesday alone has its fair share of highlighted studies.
For example, Tuesday morning, Jan D. Blankensteijn, MD, will discuss how and why the late results of the Dutch Randomised Endovascular Aneurysm Management () and the Standard Open Surgery Versus Endovascular Repair of Abdominal Aortic Aneurysm ( ) randomized controlled trials did not show the same late survival benefit for open repair as for EVAR and will address the issue of whether EVAR should be the treatment of choice for all anatomically suitable AAA patients.
Intracranial treatments for stroke will be a key interest of three trial presentations: Colin P. Derdeyn, MD, will present new findings from the Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis () randomized controlled trial comparing intracranial stenting to best medical treatments, highlighting the high incidence of in-stent restenosis causing strokes that were observed. Alejandro M. Spiotta, MD, will discuss how the COMPASS Trial: a Direct Aspiration First Pass Technique ( ) shows that new aspiration systems are equivalent to stentrievers for removing intracranial clots to treat acute strokes, and address when they appear to be actually better. In addition, L. Nelson Hopkins, MD, will present an update on the value of intracranial clot removal for acute strokes, highlighting the question of when a longer window after symptom onset (up to 24 hours) is acceptable, as seen in recent trials such as the Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo ( ) and Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke ( ) studies.
Switching gears later in the day, the 1-year results of the Bare Metal Stent Versus Paclitaxel Eluting Stent in the Setting of Primary Stenting of Intermediate Length Femoropopliteal Lesions () multicenter randomized controlled trial, will be presented by Yann Gouëffic, MD, PhD.
Be sure to catch up with these trial results and others on Tuesday and the host of trials to be presented and discussed throughout the week at the 2018 VEITHsymposium.